Remedy revenue drops 40% as CONTROL Resonant nears launch; Alan Wake 2 tops 3 million sales

Remedy Entertainment has reported a sharp revenue decline for the second quarter of 2026, but the studio says demand for its upcoming sequel CONTROL Resonant remains strong ahead of its September 24 release.

Revenue for April–June 2026 fell 40% year-over-year to €10.2 million, down from €16.9 million in the same period last year. For the full first half of 2026, revenue dropped 23.1% to €23.3 million from €30.3 million, while EBITDA stayed marginally positive at €0.5 million and operating cash flow improved to €7.6 million, helped by favorable payment timing.

CEO Jean-Charles Gaudechon, who took the role in March 2026, attributed the decline mainly to a tough comparison: Q2 2025 included a large revenue boost from the launch of FBC: Firebreak, with initial subscription-service accruals inflating last year's figures. Development fees from the Max Payne 1&2 remake and CONTROL Resonant totaled €6.4 million for the quarter, while game sales and royalties fell to €3.8 million from €9.5 million.

Despite the year-over-year drop, Remedy noted that the original Control continued growing sales momentum in Q2, partly driven by renewed franchise interest from the sequel's marketing push. Alan Wake 2 also crossed a significant milestone during the quarter, with lifetime sales exceeding 3 million copies.

The centerpiece of the report is the imminent launch of CONTROL Resonant, confirmed for a worldwide release on September 24, 2026. Remedy says the response has been strongly positive, singling out the game's shift toward faster, melee-led combat as the most debated but ultimately well-received change. The game has already surpassed 1.5 million wishlists across platforms.

On PlayStation, Remedy's internal analytics reportedly show CONTROL Resonant ranking among the top three most pre-ordered games in the US, Germany, and Brazil during its post-announcement campaign window. Marketing spend for the game ramped up significantly in Q2, which the company flagged as a driver of weaker profitability: other operating expenses rose by €1.7 million largely due to promotional activity.

Remedy currently lists three active projects: CONTROL Resonant (full production, self-published), and two others whose details have not been disclosed.